| Literature DB >> 32415523 |
Francesco Varone1, Bruno Iovene1, Giacomo Sgalla1, Mariarosaria Calvello2, Angelo Calabrese1, Anna Rita Larici1,3, Luca Richeldi1,3.
Abstract
Fibrotic hypersensitivity pneumonitis is a complex interstitial lung disease that is not entirely understood. In its chronic and fibrotic form, hypersensitivity pneumonitis is one of the main mimickers of idiopathic pulmonary fibrosis (IPF). Distinguishing between these two conditions is challenging but is of particular clinical relevance. Two approved therapies are available for IPF, and a considerable number of clinical trials are now exploring newer pharmacological options. This impressive research effort is a consequence of new pathogenetic understanding, updated diagnostic criteria and a long history of pharmacological trials. Conversely, current knowledge gaps on pathogenesis of chronic hypersensitivity pneumonitis, coupled with lack of validated diagnostic criteria, make the management of this disease an unsolved clinical challenge. This also reflects the paucity of therapeutic clinical trials in this field. In this review, we describe the current evidence and the possible future options to approach this complex disease.Entities:
Keywords: Antifibrotic treatment; Exposures; Immunosuppression; Lung fibrosis; Multidisciplinary management; UIP-like pattern
Mesh:
Year: 2020 PMID: 32415523 DOI: 10.1007/s00408-020-00360-3
Source DB: PubMed Journal: Lung ISSN: 0341-2040 Impact factor: 2.584